EN 简
About CARsgen®
We focus on innovative CAR T-cell therapies

We are biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases.

Read More
About CARsgen<sup>®</sup>
Pipeline
Pipeline
Innovative and differentiated product pipeline

We develop innovative CAR-T technologies to empower the next generation pipeline products.

Read More
We have built an integrated cell therapy platform
<p>THANK-uCAR<sup>®</sup></p>

THANK-uCAR®

Allogeneic CAR-T platform
<p>CycloCAR<sup>®</sup></p>

CycloCAR®

Cytokine and Chemokine Loaded CAR
<p>LADAR<sup>®</sup></p>

LADAR®

Local Action Driven by Artificial Receptor
News Center
2025-03-19
CARsgen Announced 2024 Annual Results
2025-03-03
CARsgen’s Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA
2025-02-28
CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease
2025-02-25
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
2025-02-10
CARsgen’s First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4
2025-01-20
CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial